DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Erinna - 1 Gilgamesh - 1 Grisey - 1 Mireille Deguy - 1 ” - 1 “ You’ll - 1 Deguy - 1
Top related locs:
Milan Paris
Top related orgs:
Paris Conservatory - 1

Search resuls for: "Gilgamesh"


4 mentions found


☆ Did Gérard Grisey’s Music Predict His Own Death?
  + stars: | 2023-08-18 | by ( Jeffrey Arlo Brown | ) www.nytimes.com   time to read: +1 min
And in the final two movements, the singer, inhabiting the character of Gilgamesh, describes the myth’s apocalyptic flood and its aftermath. In the fifth and final piece, not a complete song but a short “Lullaby,” a crystalline, pulsing texture is there one second and gone the next. On the early morning of Nov. 10, 1998, Grisey returned from Milan to the Paris apartment he shared with his partner, the mezzo-soprano Mireille Deguy. Deguy returned to their apartment in the evening. Deguy remembers that Grisey removed his watch and asked her to do the same before he collapsed from a brain aneurysm.
Persons: Erinna, Gilgamesh, Grisey, Mireille Deguy, ”, “ You’ll, Deguy Organizations: Paris Conservatory Locations: Milan, Paris
☆ Wall Street Backs New Class of Psychedelic Drugs
  + stars: | 2023-02-23 | by ( Matt Wirz | ) www.wsj.com   time to read: 1 min
Wall Street is betting tens of millions of dollars on psychedelic drugs that backers say could treat mental illness for a fraction of what it costs to do therapy with better-known treatments. Transcend Therapeutics Inc. raised $40 million from venture-capital investors in January to develop a post-traumatic stress disorder treatment that its 29-year-old CEO Blake Mandell says would require about half the amount of therapy as MDMA, or ecstasy, a popular hallucinogen. Gilgamesh Pharmaceuticals Inc. and Lusaris Therapeutics Inc. have announced capital raises of about $100 million since November for similar products addressing depression.
☆ A Y Combinator-backed startup just raised $39 million to develop new psychedelic treatments for depression
  + stars: | 2022-12-15 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +5 min
The company is creating psychedelic drugs that work faster and may not have hallucinogenic effects. The company just raised $39 million from investors and plans to start clinical trials next year. One of the treatments in development is called GM-1020 and is similar to ketamine, a dissociative anesthetic with hallucinogenic effects that has shown promise in treating depression. GM-2505 will have psychedelic effects, though they're expected to last just an hour. By comparison, some other psychedelic drugs in development — like psilocybin and MDMA — have hallucinatory effects that are expected to last up to 8 hours in the clinic.
☆ Mosul sculptor 'recreates what was demolished' on murals depicting Iraq history
  + stars: | 2022-09-22 | by ( ) www.reuters.com   time to read: +2 min
Sept 22 (Reuters) - Iraqi sculptor Khaled Al-Abadi's carefully chiselled engravings of lions, chariots, and birds decorate his Mosul workshop - the fulfilment of a dream to "to recreate what was demolished" during turbulent years of war. "During the Islamic State period, when my colleague and I were walking around, we would see the statues that were removed, and the gates that were being demolished, we were really troubled by this," Al-Abadi told Reuters. His clay-based murals reflect the country's long history – from the Assyrian period through to the Islamic State occupation. Register now for FREE unlimited access to Reuters.com Register1/4 The sculptor Khaled al-Abadi works inside his workshop on his sculptures which depict scenes from the history of the city of Mosul, in Mosul, Iraq, September 15, 2022. "This is the history of Mosul.
0 next >>
Total: 4